Over the past decade, new insights into the biology of multiple myeloma (MM) have provided the framework for the development of novel therapies to overcome drug resistance. In particular, recognition of the pivotal role of bone marrow microenvironment in promoting myeloma cell growth, survival, drug resistance, and migration has allowed for identification of specific therapeutic strategies targeting myeloma– stromal cell interactions and cytokine secretion in the bone marrow milieu. The first-in-class proteasome inhibitor bortezomib is an excellent example of this novel class of agents that has quickly translated from the bench to the bedside.
Cavo M., Pallotti M.C., Pantani L., Petrucci A., Brioli A., Terragna C., et al. (2008). Proteasome inhibitors: Bortezomib in multiple myeloma. HEMATOLOGY MEETING REPORTS, 2(5), 127-132.
Proteasome inhibitors: Bortezomib in multiple myeloma
Cavo M.;Pallotti M. C.;Pantani L.;Petrucci A.;Brioli A.;Terragna C.;Testoni N.;Marzocchi G.;Durante S.;Ceccolini M.;Perrone G.;Tacchetti P.;Zamagni E.;Tosi P.;Baccarani M.
2008
Abstract
Over the past decade, new insights into the biology of multiple myeloma (MM) have provided the framework for the development of novel therapies to overcome drug resistance. In particular, recognition of the pivotal role of bone marrow microenvironment in promoting myeloma cell growth, survival, drug resistance, and migration has allowed for identification of specific therapeutic strategies targeting myeloma– stromal cell interactions and cytokine secretion in the bone marrow milieu. The first-in-class proteasome inhibitor bortezomib is an excellent example of this novel class of agents that has quickly translated from the bench to the bedside.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
